AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Institutional Ownership: A Key Indicator for Arrowhead Pharmaceuticals' Stock Performance
ByAinvest
Monday, Sep 1, 2025 6:39 am ET1min read
Arrowhead Pharmaceuticals' stock price is sensitive to institutional trading actions, with a total of 8 investors holding 51% ownership. Analyst forecasts and ownership data suggest a strong business prospect. Institutional investors, who own 69% of the company, experienced a 6.4% increase in share price last week despite a 7.6% one-year loss.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has seen significant institutional involvement in its stock, with a total of 8 investors holding 51% ownership. This high level of institutional ownership makes the stock price particularly sensitive to trading actions by these investors [1].The company's stock experienced a 6.4% increase last week, despite a 7.6% one-year loss, indicating that institutional investors are bullish on the company's prospects. The largest shareholder is BlackRock, Inc., which owns 14% of the shares, followed by other notable institutional investors such as Vanguard Group and T. Rowe Price Investment Management Inc. [1].
Analyst forecasts also suggest a strong business outlook for Arrowhead Pharmaceuticals. The company's stock has been covered by several analysts, with a mix of "buy" and "strong-buy" ratings, indicating optimism about the company's future performance. Despite recent earnings missing analyst expectations, the company's revenue and earnings per share (EPS) have shown signs of improvement [2].
Institutional ownership and analyst forecasts provide valuable insights into Arrowhead Pharmaceuticals' prospects. However, investors should also consider other factors, such as the company's earnings history and financial health, when making investment decisions. The company's stock has a market capitalization of $2.95 billion, a P/E ratio of -16.66, and a beta of 0.94, indicating a relatively low risk compared to the broader market [2].
References:
[1] https://finance.yahoo.com/news/arrowhead-pharmaceuticals-inc-nasdaq-arwr-101903529.html
[2] https://www.marketbeat.com/instant-alerts/filing-pale-fire-capital-se-takes-position-in-arrowhead-pharmaceuticals-inc-arwr-2025-08-24/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet